Teva Announces New Direct Relief Patient Access Program to Provide Inhaler Access to Uninsured Patients | 11.12.24

• Teva has provide two generic inhaler products Direct Relief for its network of
  free And
  charity clinics
• The programthrowhinge this month, will last at least three years

PARSIPPANY, NJ, December 11, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, Inc., a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of a new patient access program, in partnership with Direct Relief, to provide free inhalers to eligible patients in the United States.

“In the United States, while 93% of Teva’s inhaled medications are generic products available at lower prices – especially for insured patients – there are still uninsured patients who do not have access to affordable generic inhalers said Chris Fox, executive vice president of U.S. Commercial. at Teva. “The goal of this program is to help address an unmet need in underserved communities across the country, by improving patient access to safe, affordable medications delivered via inhalers, including inhalation inhalers. maintenance and rescue. »

Teva will offer two inhalers under this program: generic versions of AirDuo®RespiClick® (fluticasone propionate/salmeterol xinafoate maintenance inhaler) and ProAir® HFA (albuterol sulfate rescue inhaler) . Teva will donate the inhalers to Direct Relief for on-demand distribution to free and charitable clinics, for distribution to uninsured patients served by those clinics.

“Direct Relief is deeply grateful to Teva for this critical donation that will provide patients with access to respiratory treatments they would not otherwise have access to,” said Katie Lewis, regional director of U.S. programs for Direct Relief. “Free and charitable clinics provide quality care to underserved communities, and this donation will allow them to reach even more patients with these medications.” »

The program will continue for at least three years to ensure a reliable and continuous supply to these patients. In addition to donating the inhalers, Teva will make a cash donation to Direct Relief to cover the costs of administering this program.

Direct Relief, Teva’s long-time partner in medicine access programs in the United States and around the world, is a nonprofit humanitarian organization that provides medical resources to resource-poor communities. She manages, on her own behalf, the largest charitable medical program in the United States. Through its network, Direct Relief supports the distribution of free, high-quality medications to low-income and uninsured patients at the point of care, making it easier for patients to access needed medications.

About Teva

(NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, leveraging our generics expertise and accelerating innovation to continue the momentum behind the discovery, delivery and expanded development of medicine modern. For more than 120 years, Teva’s commitment to improving health has never wavered. Today, the company’s global network of capabilities enables its approximately 37,000 employees in 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes for millions of people. patients every day. To learn more about how Teva contributes to better health, visit www.tevapharm.com.

Caution Regarding Forward-Looking Statements

This document and the conference presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to significant, known and known risks and uncertainties. unknown. which could cause our future results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks related to: our ability to make both of our inhalers available through the new patient access program; our ability to compete successfully in the marketplace, including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations generally, including the impact of global economic conditions and other macroeconomic developments and governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections titled “Risk Factors “. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. are cautioned not to place undue reliance on these forward-looking statements.